Athanasia Dasargyri will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

Athanasia Dasargyri of CDR-Life will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

In antibody therapeutics, large pharma continues to pay for platforms that explicitly address therapeutic index. The 百时美施贵宝-Janux Therapeutics collaboration around a tumor-activated T cell engager reinforces that conditional activation remains one of the most credible strategies for expanding the use of TCEs in solid tumors. When platform design is anchored in safety control rather than brute-force potency, preclinical assets can still command meaningful economics. A similar logic appears in autoimmune disease. 勃林格殷格翰’s billion-euro-scale bet on a TL1A×IL-23 bispecific reflects confidence that pathway convergence, rather than incremental single-target optimization, may be required to reset efficacy ceilings in chronic inflammatory diseases. Importantly, these deals continue to offload late-stage clinical and commercial execution to scaled operators, allowing early innovators to monetize platform risk earlier. What stands out this week, however, is the contrast provided by gene medicine. 礼来’s >$1.1B collaboration with Seamless Therapeutics around a programmable recombinease platform for hereditary hearing loss highlights that gene therapy capital is re-entering the market—but in a more disciplined form. The emphasis is no longer on editing novelty alone, but on programmability, precision, and clinical tractability. In many ways, this mirrors where antibody investing was a decade ago. Two cross-modality patterns are becoming clearer: - Platform optionality is favored over single-asset heroics - Safety, controllability, and manufacturability increasingly drive valuation - Big pharma prefers structured deals that preserve downside while securing long-term upside The antibody and gene therapy worlds are converging—not in modality, but in investment logic. The next winners will be platforms that convert uncertainty into engineering problems.

This week’s deal flow sends a clean signal: capital is not retreating from innovation—it is becoming more selective about where technical risk is taken and how it is transferred.
#BCIC #BiotechInvesting #AntibodyTherapeutics
#TCellEngagers #BispecificAntibodies #ADC
#GeneTherapy #RareDisease

Hypoxia-driven MUC16/CA125 downregulation, #VEGF secretion, and #EMT emerge as #tumor-intrinsic mechanisms of resistance to MUC16-directed bispecific #TcellEngagers in #OvarianCancer, and VEGF blockade restores #cytotoxicity. @harvardmed.bsky.social

#STTT: doi.org/10.1038/s413...

T cell engagers emerge as a compelling therapeutic modality. New review from Baeuerle, Grieshaber-Bouyer, Sauer, and Michaelson: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #TcellEngagers

#TcellEngagers (#TCEs) are engineered to redirect the body’s #Tcells toward disease. Their versatility, expanding target range, and growing clinical impact are redefining immune-based therapy. In a new review, Baeuerle et al. describe why they’re rising so quickly.: rupress.org/jem/article/...

#TcellEngagers (#TCEs) are engineered to redirect the body’s #Tcells toward disease. Their versatility, expanding target range, and growing clinical impact are redefining immune-based therapy. In a @jem.org review, Baeuerle et al. describe why they’re rising so quickly.: rupress.org/jem/article/...

CDR-Life is at #BIOEquityEurope! CEO Christian Leisner is sharing how our M-gager® T cell engagers are advancing solid tumor & autoimmune therapies. Meet in person or join virtual partnering next week to connect. #TCellEngagers

Wonderful opportunity to #share & #discuss emerging role of #TCellEngagers #BiTEs in Mx of #SCLC 🫁 w/ our Malaysian 🇲🇾 colleagues during #LCS2025.

Small group discussions (esp. over a meal! 😋) are always very interactive for experience sharing.

#LCSM @APCLC_2023 @apoddc @cuhkmedicine.bsky.social

Heading to Milan for BIO-Europe Spring! Our Chief Business Officer @Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatment—plus what’s ahead for our innovative M-gager® platform. Let’s connect! #BIOEuropeSpring
#TCellEngagers